1. Taiwan, Province of China Stocks

  2. •

    Technology

  3. •

    Consumer Electronics
Medeon Biodesign, Inc.

Medeon Biodesign, Inc.

6499.TWO
Medeon Biodesign, Inc.TW flagTaipei Exchange
73.20
TWD
+0.50
- -
7.10BMarket Cap

Total Valuation

Medeon Biodesign, Inc. carries a market capitalization of 7.10B, placing it among publicly traded companies globally. Its enterprise value stands at 11.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap7.10B
Enterprise Value11.12B

Share Statistics

Medeon Biodesign, Inc. currently has 92.24M shares outstanding.

Shares Outstanding92.24M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 29.81, and the price-to-book ratio stands at -24.42.

PE RatioN/A
PS Ratio29.81
PB Ratio-24.42
P/TBV Ratio12.05
P/FCF Ratio-16.87
P/OCF Ratio-15.87

Enterprise Valuation

EV / Sales28.21
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Medeon Biodesign, Inc. maintains a current ratio of 5.03, meaning it holds 5.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.03, indicating elevated leverage, while an interest coverage ratio of -171.83 demonstrates limited ability to service its debt obligations.

Current Ratio5.03
Quick Ratio4.38
Debt / Equity12.03
Debt / EBITDA-0.17
Interest Coverage-171.83

Financial Efficiency

Return on Equity (ROE)-152.18
Return on Assets (ROA)-40.33
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover13.06

Taxes

Income Tax-756,000.00
Effective Tax RateN/A

Stock Price Statistics

Medeon Biodesign, Inc.'s stock has declined approximately -49.51724% over the past 52 weeks. The 50-day moving average sits at 80.30, while the 200-day moving average is 91.89.

Beta (5Y)N/A
52-Week Price Change-49.51724%
50-Day Moving Average80.30
200-Day Moving Average91.89
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Medeon Biodesign, Inc. generated 394.40M in revenue and converted that into -749.38M in net income, yielding earnings per share of -8.74. EBITDA reached -796.09M, while operating income came in at -796.09M.

Revenue394.40M
Gross Profit101.12M
Operating Income-796.09M
Pretax Income-806.85M
Net Income-749.38M
EBITDA-796.09M
EBIT-796.09M
Earnings Per Share (EPS)-8.74

Balance Sheet

Medeon Biodesign, Inc. holds 798.05M in cash and equivalents against 136.25M in total debt, resulting in a net debt position of -693.43M. Total book value stands at -481.49M, with working capital of 735.50M providing operational flexibility.

Cash & Cash Equivalents798.05M
Total Debt136.25M
Net Debt-693.43M
Equity (Book Value)-481.49M
Book Value Per Share-5.22
Working Capital735.50M

Cash Flow

Medeon Biodesign, Inc. produced -740.86M in operating cash flow over the past twelve months. After subtracting -43.90M in capital expenditures, free cash flow totaled -784.77M - equivalent to -8.51 per share.

Operating Cash Flow-740.86M
Capital Expenditures-43.90M
Free Cash Flow-784.77M
FCF Per Share-8.51

Margins

Medeon Biodesign, Inc. operates with a gross margin of 25.64, reflecting its pricing power and cost economics. The operating margin of -201.85 and net profit margin of -190.00 provide insight into operational efficiency.

Gross Margin25.64
Operating Margin-201.85
Pretax Margin-204.58
Profit Margin-190.00
EBITDA Margin-201.85

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield0.40
FCF Yield-5.93

Stock Splits

Medeon Biodesign, Inc.'s most recent stock split took place on August 23, 2023 with a 1000:1049 split ratio.

Last Split Date8/23/2023
Split Ratio1000:1049

Scores

Medeon Biodesign, Inc. posts an Altman Z-Score of 22.16, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score22.16